DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group Jul 2, 2008
QUEBEC CITY, July 2 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that Dr. Timothy J. Holzer, Vice President, RProduction at DiagnoCure, and Dr. Scott Waldman, from Thomas Jefferson University, were speakers on June 29, 2008, in Boston, Massachusetts, in a session at the Eastern Cooperative Oncology Group (ECOG), one of the largest clinical cancer research organizations in... (Canada Newswire)
New 'everyday cognition' scale tracks how older adults function in daily life Jul 1, 2008
A new, carefully validated questionnaire called Everyday Cognition (ECog), when filled out by someone who knows an older adult well, can sensitively evaluate the performance of everyday activities that reflect basic mental functioning, according to a report in the July issue of Neuropsychology, published by the American Psychological Association ... The ECog was shown to be valid in several ways ... By differentiating among people with normal cognition, Mild Cognitive Impairment (MCI), and... (EurekAlert!)
Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies Jun 1, 2008
The research for the second study, "Predictive utility of progesterone receptor and multigene expression in identifying benefit from adjuvant doxorubicin plus cyclophosphamide or docetaxel in intergroup trial E2197," (abstract 557) was led by the Eastern Cooperative Oncology Group (ECOG). Researchers evaluated the predictive utility of progesterone receptor (PR) protein expression by IHC in a central lab and quantitative RNA expression by RT-PCR for 371 genes, including the current Oncotype DX... (PR Newswire)
Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting May 16, 2008
Poster discussion period: 11:00 AM - 12:00 p.m., W375a -- Comparison of kidney cancer symptoms and quality of life (QoL) in renal cell cancer (RCC) patients receiving sorafenib vs. interferon-a (IFN) -- Cezary Szczylik, MD, Central Clinical Hospital, Military Institute of Health, Warsaw, Poland -- Poster 44E, Abstract #9603, Saturday, May 31, 2008, 2:00 - 6:00 p.m., S Hall A1 -- Updated results of a Phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell carcinoma (RCC)... (PR Newswire)
European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review Apr 2, 2008
SEATTLE, April 2, 2008 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: ; MTA) today announced that the European Medicines Agency (EMEA) has accepted for review CTI's Marketing Authorization Application (MAA) for XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of patients with non-small cell lung cancer (NSCLC) with ECOG (Eastern Cooperative Oncology Group) performance status 2 (PS2). CTI submitted the MAA at the beginning of March. (PR Newswire)
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) Mar 4, 2008
XYOTAX to be reviewed for PS2 first-line non-small cell lung cancer indication SEATTLE, March 4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of patients with non-small cell lung cancer (NSCLC) who have ECOG (Eastern Cooperative Oncology Group) performance status 2 (PS2). The... (PR Newswire)
New study of targeted therapies for breast cancer -- model for global clinical trials Feb 29, 2008
" Lapatinib, in combination with the chemotherapy drug capecitabine, was approved by the U.S. Food and Drug Administration in March 2007 for the treatment of advanced or metastatic HER2-positive breast cancer in patients who had received prior therapy with three agents -- an anthracycline, a taxane and Herceptin. GlaxoSmithKline is providing the study drug, as well as additional financial support for the ALTTO trial. All drugs carry potential side effects, and more information of side effects... (EurekAlert!)
Taxol with avastin produces noteworthy results Dec 28, 2007
The study was coordinated by the Eastern Cooperative Oncology Group (ECOG) and Kathy Miller, M.D., associate professor of medicine and Sheila D. Ward Scholar at the Indiana University School of Medicine, is the lead author. Dr. Miller said she found the results exciting because this was the first study to show that an antiangiogenic agent can delay progression of advanced breast cancer. (EurekAlert!)
Bevacizumab found to improve survival for patients with advanced breast cancer Dec 27, 2007
Rush University Medical Center participated in the clinical trial which was sponsored by the National Cancer Institute and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG). The study of 722 women with recurrent (metastatic) breast cancer found that the women who received Avastin in combination with standard chemotherapy had a doubling of delay in worsening of their cancer by approximately five months, on average, compared to patients treated with... (EurekAlert!)
Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule Dec 18, 2007
CTI plans to submit an MAA in Europe, based on the STELLAR 4 phase III clinical trial results, for XYOTAX as a single agent for first-line treatment of non-small cell lung cancer (NSCLC) in patients with poor performance status (ECOG performance status 2, PS2). "The meetings were very productive and we appreciate the advice the rapporteurs provided us on how best to report our data and supporting literature for the utility of the comparator drugs gemcitabine and vinorelbine," said Scott C.... (PR Newswire)
Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer Dec 17, 2007
The study was sponsored by the National Cancer Institute (NCI), part of the US National Institutes of Health, and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG). Patients were sequentially assigned to one of two treatment arms: -- Treatment arm A received dose-dense combination of doxorubicin and cyclophosphamide with Avastin, followed by paclitaxel and Avastin, followed by Avastin alone. (PR Newswire)
Genomic Health Announces Oncotype DX(R) Provides Additional Prognostic Benefit in Patients Assessed With Adjuvant Online Dec 16, 2007
"These results, combined with updated ASCO treatment guidelines now recommending Oncotype DX, clearly demonstrate that Oncotype DX provides critical information for breast cancer treatment planning that is not apparent by examination of clinical variables alone." The comparison study assessed 465 patients with hormone receptor-positive breast cancer from a previous Eastern Cooperative Oncology Group (ECOG) study, computing both the Adjuvant Online risk estimate and Oncotype DX Recurrence Score... (PR Newswire)
The International Myeloma Foundation Says New Findings Reported at Global Cancer Conference Require New Ways to Evaluate Treatments: Survival and Long Dec 14, 2007
Findings from a multi-center clinical trial sponsored by the National Cancer Institute and led by the Eastern Cooperative Oncology Group (ECOG) demonstrated that lowering the dose of the steroid dexamethasone when paired with REVLIMID to treat newly diagnosed myeloma, not only reduces side effects, but also improves long-term survival ... Findings from a multi-center clinical trial sponsored by the National Cancer Institute and led by the Eastern Cooperative Oncology Group (ECOG) demonstrated... (Yahoo News -- Press Releases)
Ireland Cancer Center researchers advance stem cell gene therapy Dec 13, 2007
Dr. Lazarus and colleagues of the Eastern Cooperative Oncology Group (ECOG) presented data that show that Imatninib (Gleevec) does not change outcomes on patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Dr. Lazarus presented an assessment of data over 30 years regarding acute leukemia and its management. (EurekAlert!)
Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer Sep 24, 2007
"An analysis of recent Eastern Cooperate Oncology Group (ECOG) studies presented at the World Conference on Lung Cancer shows that women under 45 years old, presumably pre-menopausal, have worse outcomes than older women who are over 60," said Jack W. Singer, M.D., Chief Medical Officer at CTI. "This data, coupled with the recent Southwest Oncology Group (SWOG) analysis that also showed women under 60 had shorter survival, underscores the potential importance of the survival advantage we... (PR Newswire)
Revlimid data presented at ASCO stands to change the way physicians treat multiple myeloma Jun 5, 2007
Tampa, FL -- (June 4, 2007) -- Findings from a Phase III study by the Eastern Cooperative Oncology Group (ECOG 4A03) were presented yesterday at the American Society of Clinical Oncology (ASCO) meeting in Chicago and demonstrate the benefits of using Revlimid (lenalidomide) with reduced doses of the steroid dexamethasone ... "Because of the strong one-year survival data seen in the ECOG trial, we think there is a need to continue to evaluate novel treatment options. The development of new... (EurekAlert!)
Genomic Health, Inc. Announces Positive Results from First Study Using Oncotype DX(TM) in Node-Positive Breast Cancer Patients Jun 4, 2007
Second Study Underway to Determine If Oncotype DX Predictsthe Magnitude of Chemotherapy Benefit in Node-Positive Breast Cancer Patients Recommendation to Use Oncotype DX in Node-Positive Breast CancerWill Be Based on Results of Second Ongoing Study CHICAGO, June 3 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive results of a first study analyzing patient samples from a large trial conducted by the Eastern Cooperative Oncology Group (ECOG), a National Cancer... (PR Newswire)
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival Jun 3, 2007
An ECOG 0-1 Performance Status was maintained in 83 percent of patients during the maintenance phase. These data represent the planned final analysis with a median follow-up of 3. (PR Newswire)
ASCO Awards First 'Team Science' Distinguished Service Award to Cancer Cooperative Groups Jun 2, 2007
Ten Community Practices Recognized for Clinical Trial Achievements CHICAGO, June 1 /PRNewswire-USNewswire/ -- The Cancer Cooperative Groups this year will become the first group to receive a Distinguished Service Award for Scientific Leadership from the American Society of Clinical Oncology (ASCO), while ten community oncology practices will be honored with Clinical Trials Participation Awards - an annual ASCO honor sponsored by the Coalition of Cancer Cooperative Groups that recognizes... (PR Newswire)
The International Myeloma Foundation Reports Positive Shift In Treatment Paradigm For Patients May 16, 2007
-- In April, the Eastern Cooperative Oncology Group (ECOG) stopped the use of high dose dexamethasone, a steroid commonly used when treating patients with REVLIMID, (lenalidomide) an oral medication from Celgene ... "Based on this new clinical evidence, we believe that regimens that include REVLIMID with low dose steroid are an important option for patients with myeloma at all stages of the disease." Susie Novis, president and co-founder of the IMF, added, "These findings are particularly... (PR Newswire)
Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP Phase II Trial Apr 26, 2007
CLINICAL APPENDIX The following additional information is provided in accordance with the Code of Best Practice for ASX Reporting by Life Science Companies Trial Title Randomised Phase II Trial of irinotecan with Hyaluronic Acid (HyCAMP(TM)) versus irinotecan as treatment for patients with metastatic colorectal cancer who have failed 5-FU based chemotherapy Blinding Status Open label, randomised Treatment Method HyCAMP(TM) arm: Irinotecan: 350mg/mm2 day 1 every 3 weeks or 300 mg/mm2 day 1 every... (PR Newswire)
Multiple myeloma clinical trial closes early Apr 5, 2007
The study led by the Eastern Cooperative Oncology Group (ECOG) and supported by the National Cancer Institute compared combination treatment of oral medications lenalidomide and either high- or low-dose dexamethasone in 445 patients with newly-diagnosed myeloma ... "In my opinion, this is the best one-year survival data that Ive seen in a large phase 3 study in myeloma," says Vincent Rajkumar, M.D., Mayo Clinic hematologist and primary investigator of the ECOG study. (EurekAlert!)
Celgene Corporation Reviews 2006 Achievements and Announces 2007 Financial Outlook Jan 9, 2007
00 - 2007 Milestones - REVLIMID EMEA Approval - REVLIMID European Launches Following Local price, Reimbursement and Distribution Approvals - Initiate REVLIMID CLL hase III SPA Trials - REVLIMID Newly Diagnosed Multiple Myeloma Phase III Data from ECOG E4A03Trial - Advance CC-10004 in PDE4/TNF Indications - Initiate Regulatory Studies for CC-4047 in Hematology and Solid Tumors SUMMIT, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: ) reviewed recent corporate highlights and... (PR Newswire)
New England Journal of Medicine Publishes Data from Pivotal Study of Avastin Plus Chemotherapy in Most Common Type of Lung Cancer Dec 14, 2006
The trial was conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG). E4599 Safety Analysis According to the study published in the New England Journal of Medicine, the rates of the following severe (Grade 3-5 for non-hematologic and Grade 4-5 for hematologic) adverse events were significantly higher in patients receiving Avastin plus chemotherapy compared to patients receiving chemotherapy alone: hypertension (high blood pressure), proteinuria, bleeding,... (PR Newswire)
FDA Approves Avastin(R) in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer Oct 12, 2006
The trial was conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG) ... Based on this trial, ECOG and NCI selected the higher dose for the pivotal Phase III trial in NSCLC. The typical monthly cost of Avastin at this dose is approximately $8,800 and, based on median progression-free survival as measured in the E4599 trial, the average cost per course of therapy in NSCLC is approximately $56,000. (PR Newswire)
Teenager Moves Video Icons Just By Imagination Oct 12, 2006
The teenager had a grid atop his brain to record brain surface signals, a brain-machine interface technique that uses electrocorticographic (ECoG) activity - data taken invasively right from the brain surface ... With approval of the patient and his parents and the Washington University School of Medicine Institutional Review Board, Leuthardt and Moran connected the patient to a sophisticated computer running a special program known as BCI2000 (developed by their collaborator Gerwin Schalk at... (Science Daily)
FDA Approves Avastin(R) in Combination With Chemotherapy for Second-Line Metastatic Colorectal Cancer Patients Jun 21, 2006
The trial was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG). Genentech provided Avastin for the trial under the Cooperative Research and Development Agreement (CRADA) with the NCI for the clinical development of Avastin, as well as financial support for data management. (PR Newswire)
Researchers announce new predictor for lung cancer treatment and survival Jun 6, 2006
Data was analyzed from a phase III study, conducted by the Eastern Cooperative Oncology Group (ECOG), which involved 878 patients nationwide who were randomized to standard chemotherapy - paclitaxel and carboplatin - with and without Bevacizumab. Patients who received Bevacizumab lived 2. (EurekAlert!)
Data from XYOTAX(TM) STELLAR Trials Presented at 2006 Meeting of American Society of Clinical Oncology Jun 5, 2006
O'Brien concluded that weight loss, presence of extra-thoracic metastasis, low LCS (lung cancer symptom) scores, and high LDH (lactate dehydrogenase -- a tumor marker) were significant negative prognostic factors for PS2 (ECOG performance status 2) patients with NSCLC. Significant differences in survival based on geographic region seen in STELLAR 3 highlighted the importance of stratification by region. Subgroup analysis by randomization strata showed no difference in survival between treatment... (PR Newswire)
Addition of Thalidomide to Standard Therapy Improves Overall Survival in Newly Diagnosed Multiple Myeloma Jun 5, 2006
The Company expects this application will include data from four Phase III clinical studies in patients with newly diagnosed multiple myeloma: -- IFM clinical study: melphalan/prednisone compared to melphalan/prednisone plus thalidomide or autologous stem cell transplantation -- GIMEMA clinical study: melphalan/prednisone compared to melphalan/prednisone plus thalidomide -- ECOG clinical study: thalidomide/dexamethasone compared to dexamethasone -- A pivotal study sponsored by Celgene and... (PR Newswire)
Lorus announces presentation of data from four clinical trials with three different drugs at the 2006 American Society of Clinical Oncology (ASCO) Meeting Jun 1, 2006
Patients with either low ECOG scores (better overall performance), or patients with metastatic disease, had increased survival times that approached statistical significance. In addition, exploratory analysis of data from patients that continued treatment with Virulizin(R) during second line therapy demonstrated significant increases in survival. (Canada Newswire)
Loud Music Worsens Effects Of Taking Ecstasy Feb 25, 2006
The electrocortical activity (EcoG spectrum) of the rats was monitored, using electrodes placed on their skull, from 60 minutes before administration of the drug and start of the music, to up to five days after the music was stopped ... However, the EcoG total spectrum of the rats given a low dose of MDMA significantly decreased once loud music was played ... The EcoG spectrum of rats in the control group was not modified by loud music. (Science Daily)
